Fraunhofer-IBMT, Germany
Dr. Ralf Kettenhofen is an employee of the Fraunhofer Institute for Biomedical Engineering IBMT with responsibilities in business development and as Senior Scientist in pluripotent stem cell sciences.
He is a chemist by training and received his PhD from the Rheinische-Friedrich-Wilhelms-University Bonn in 2000. After one year as a postdoctoral fellow Ralf joined the stem cell biotech company Axiogenesis AG, which later became Ncardia AG. He worked there for 18 years as a Senior Scientist, Head of Laboratory, Head of Production and Product Manager of pluripotent stem cell-derived cardiomyocytes before he joined Fraunhofer IBMT in 2019.
Fraunhofer IBMT is coordinating the IMI-funded EU project European Bank for induced pluripotent Stem Cells (EBiSC) with about 900 hiPSC lines banked. Ralf is involved in EBiSC’s biomaterial acquisition and marketing teams and he is currently heading the hiPS-derived cardiomyocyte group.
Since 2013 Ralf is a member of the HESI Cardiac Safety Committee and participated in the CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative in which human pluripotent stem cell-derived cardiomyocytes were successfully validated for the use in safety pharmacological studies.
ENABLING iPSC INNOVATION: EXPLORE EBiSC'S CELLS, SCIENCE, AND DATA
Thursday, July 11, 2024
6:00 PM – 6:30 PM CEST